Cargando…

The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial

Aim: Epicardial adipose tissue (EAT) may be associated with arrhythmogenesis. P-wave indices such as P-wave dispersion and P-wave variation indicated a slowed conduction velocity within the atria. This study investigated the effect of dapagliflozin on EAT volume and P-wave indices. Methods: In the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Takao, Aizawa, Yoshifusa, Yuasa, Sho, Fujita, Satoshi, Ikeda, Yoshio, Okabe, Masaaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Atherosclerosis Society 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840164/
https://www.ncbi.nlm.nih.gov/pubmed/32115470
http://dx.doi.org/10.5551/jat.48009
_version_ 1783643519013879808
author Sato, Takao
Aizawa, Yoshifusa
Yuasa, Sho
Fujita, Satoshi
Ikeda, Yoshio
Okabe, Masaaki
author_facet Sato, Takao
Aizawa, Yoshifusa
Yuasa, Sho
Fujita, Satoshi
Ikeda, Yoshio
Okabe, Masaaki
author_sort Sato, Takao
collection PubMed
description Aim: Epicardial adipose tissue (EAT) may be associated with arrhythmogenesis. P-wave indices such as P-wave dispersion and P-wave variation indicated a slowed conduction velocity within the atria. This study investigated the effect of dapagliflozin on EAT volume and P-wave indices. Methods: In the present ad hoc analysis, 35 patients with type 2 diabetes mellitus and coronary artery disease were classified into dapagliflozin group (n = 18) and conventional treatment group (n = 17). At baseline, EAT volume, HbA1c and plasma level of tumor necrotic factor-α (TNF-α) levels, echocardiography, and 12-lead electrocardiogram (ECG) were performed. EAT volume was measured using computed tomography. Using 12-lead ECG, P-wave indices were measured. Results: At baseline, EAT volumes in the dapagliflozin and conventional treatment groups were 113 ± 20 and 110 ± 27 cm(3), respectively. Not only HbA1c and plasma level of TNF-α but also echocardiography findings including left atrial dimension and P-wave indices were comparable between the two groups. After 6 months, plasma level of TNF-α as well as EAT volume significantly decreased in the dapagliflozin group only. P-wave dispersion and P-wave variation significantly decreased in the dapagliflozin group only (−9.2 ± 8.7 vs. 5.9 ± 19.9 ms, p = 0.01; −3.5 ± 3.5 vs. 1.7 ± 5.9 ms, p = 0.01). The change in P-wave dispersion correlated with changes in EAT volume and plasma level of TNF-α. In multivariate analysis, the change in EAT volume was an independent determinant of the change in P-wave dispersion. Conclusion: Dapagliflozin reduced plasma level of TNF-α, EAT volume, and P-wave indices, such as P-wave dispersion. The changes in P-wave indices were especially associated with changes in EAT volume. The number and date of registration: UMIN000035660, 24/Jan/2019
format Online
Article
Text
id pubmed-7840164
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Japan Atherosclerosis Society
record_format MEDLINE/PubMed
spelling pubmed-78401642021-02-05 The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial Sato, Takao Aizawa, Yoshifusa Yuasa, Sho Fujita, Satoshi Ikeda, Yoshio Okabe, Masaaki J Atheroscler Thromb Original Article Aim: Epicardial adipose tissue (EAT) may be associated with arrhythmogenesis. P-wave indices such as P-wave dispersion and P-wave variation indicated a slowed conduction velocity within the atria. This study investigated the effect of dapagliflozin on EAT volume and P-wave indices. Methods: In the present ad hoc analysis, 35 patients with type 2 diabetes mellitus and coronary artery disease were classified into dapagliflozin group (n = 18) and conventional treatment group (n = 17). At baseline, EAT volume, HbA1c and plasma level of tumor necrotic factor-α (TNF-α) levels, echocardiography, and 12-lead electrocardiogram (ECG) were performed. EAT volume was measured using computed tomography. Using 12-lead ECG, P-wave indices were measured. Results: At baseline, EAT volumes in the dapagliflozin and conventional treatment groups were 113 ± 20 and 110 ± 27 cm(3), respectively. Not only HbA1c and plasma level of TNF-α but also echocardiography findings including left atrial dimension and P-wave indices were comparable between the two groups. After 6 months, plasma level of TNF-α as well as EAT volume significantly decreased in the dapagliflozin group only. P-wave dispersion and P-wave variation significantly decreased in the dapagliflozin group only (−9.2 ± 8.7 vs. 5.9 ± 19.9 ms, p = 0.01; −3.5 ± 3.5 vs. 1.7 ± 5.9 ms, p = 0.01). The change in P-wave dispersion correlated with changes in EAT volume and plasma level of TNF-α. In multivariate analysis, the change in EAT volume was an independent determinant of the change in P-wave dispersion. Conclusion: Dapagliflozin reduced plasma level of TNF-α, EAT volume, and P-wave indices, such as P-wave dispersion. The changes in P-wave indices were especially associated with changes in EAT volume. The number and date of registration: UMIN000035660, 24/Jan/2019 Japan Atherosclerosis Society 2020-12-01 /pmc/articles/PMC7840164/ /pubmed/32115470 http://dx.doi.org/10.5551/jat.48009 Text en 2020 Japan Atherosclerosis Society This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Original Article
Sato, Takao
Aizawa, Yoshifusa
Yuasa, Sho
Fujita, Satoshi
Ikeda, Yoshio
Okabe, Masaaki
The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial
title The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial
title_full The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial
title_fullStr The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial
title_full_unstemmed The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial
title_short The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial
title_sort effect of dapagliflozin treatment on epicardial adipose tissue volume and p-wave indices: an ad-hoc analysis of the previous randomized clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840164/
https://www.ncbi.nlm.nih.gov/pubmed/32115470
http://dx.doi.org/10.5551/jat.48009
work_keys_str_mv AT satotakao theeffectofdapagliflozintreatmentonepicardialadiposetissuevolumeandpwaveindicesanadhocanalysisofthepreviousrandomizedclinicaltrial
AT aizawayoshifusa theeffectofdapagliflozintreatmentonepicardialadiposetissuevolumeandpwaveindicesanadhocanalysisofthepreviousrandomizedclinicaltrial
AT yuasasho theeffectofdapagliflozintreatmentonepicardialadiposetissuevolumeandpwaveindicesanadhocanalysisofthepreviousrandomizedclinicaltrial
AT fujitasatoshi theeffectofdapagliflozintreatmentonepicardialadiposetissuevolumeandpwaveindicesanadhocanalysisofthepreviousrandomizedclinicaltrial
AT ikedayoshio theeffectofdapagliflozintreatmentonepicardialadiposetissuevolumeandpwaveindicesanadhocanalysisofthepreviousrandomizedclinicaltrial
AT okabemasaaki theeffectofdapagliflozintreatmentonepicardialadiposetissuevolumeandpwaveindicesanadhocanalysisofthepreviousrandomizedclinicaltrial
AT satotakao effectofdapagliflozintreatmentonepicardialadiposetissuevolumeandpwaveindicesanadhocanalysisofthepreviousrandomizedclinicaltrial
AT aizawayoshifusa effectofdapagliflozintreatmentonepicardialadiposetissuevolumeandpwaveindicesanadhocanalysisofthepreviousrandomizedclinicaltrial
AT yuasasho effectofdapagliflozintreatmentonepicardialadiposetissuevolumeandpwaveindicesanadhocanalysisofthepreviousrandomizedclinicaltrial
AT fujitasatoshi effectofdapagliflozintreatmentonepicardialadiposetissuevolumeandpwaveindicesanadhocanalysisofthepreviousrandomizedclinicaltrial
AT ikedayoshio effectofdapagliflozintreatmentonepicardialadiposetissuevolumeandpwaveindicesanadhocanalysisofthepreviousrandomizedclinicaltrial
AT okabemasaaki effectofdapagliflozintreatmentonepicardialadiposetissuevolumeandpwaveindicesanadhocanalysisofthepreviousrandomizedclinicaltrial